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ABSTRACT
Precocious puberty is defined as the development of secondary sexual charac-
teristics before the age of 8 years in girls and 9 years in boys. Gonadotropin-
dependent precocious puberty (GDPP) results from the premature activation of 
the hypothalamic-pituitary-gonadal axis and mimics the physiological pubertal 
development, although at an inadequate chronological age. Hormonal evalua-
tion, mainly through basal and GnRH-stimulated LH levels shows activation of 
the gonadotropic axis. Gonadotropin-independent precocious puberty (GIPP) 
is the result of the secretion of sex steroids, independently from the activation 
of the gonadotropic axis. Several genetic causes, including constitutive activat-
ing mutations in the human LH-receptor gene and activating mutations in the 
Gs protein D-subunit gene are described as the etiology of testotoxicosis and 
McCune-Albright syndrome, respectively. The differential diagnosis between 
GDPP and GIPP has direct implications on the therapeutic option. Long-acting 
gonadotropin-releasing hormone (GnRH) analogs are the treatment of choice 
in GDPP. The treatment monitoring is carried out by clinical examination, hor-
monal evaluation measurements and image studies. For treatment of GIPP, 
drugs that act by blocking the action of sex steroids on their specific receptors 
(cyproterone, tamoxifen) or through their synthesis (ketoconazole, medroxy-
progesterone, aromatase inhibitors) are used. In addition, variants of the nor-
mal pubertal development include isolated forms of precocious thelarche, 
precocious pubarche and precocious menarche. Here, we provide an update 
on the etiology, diagnosis and management of sexual precocity. (Arq Bras 
Endocrinol Metab 2008;52/1:18-31)
Keywords: Precocious puberty, GnRH analogs, Precocious thelarche, Preco-
cious pu-barche, Testotoxicosis, McCune Albright syndrome.
RESUMO
Atualização em etiologia, diagnóstico e manejo da precocidade 
sexual.
A puberdade precoce é definida como o desenvolvimento dos caracteres se-
xuais secundários antes dos 8 anos nas meninas e dos 9 anos nos meninos. A 
puberdade precoce dependente de gonadotrofinas (PPDG) resulta da ativação 
prematura do eixo hipotálamo-hipófise-gonadal e mimetiza o desenvolvimen-
to puberal fisiológico, embora em idade cronológica inadequada. A avaliação 
hormonal, principalmente os valores de LH basal e após estímulo com GnRH
exógeno confirmam a ativação do eixo gonadotrófico. A puberdade precoce 
independente de gonadotrofinas (PPIG) é o resultado da secreção de esteróides 
sexuais independentemente da ativação do eixo gonadotrófico. Diversas cau-
sas genéticas, incluindo mutações ativadoras constitutivas no gene do recep-
tor do LH humano e mutações ativadoras no gene da subunidade D da proteína 
G representam as etiologias da testotoxicose e da síndrome de McCune Al-
bright, respectivamente. O diagnóstico diferencial entre PPDG e PPIG tem im-
plicação direta na opção terapêutica. Análogos de GnRH de ação prolongada é 
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Table 1. Classification of the precocious puberty.
Gonadotropin-dependent precocious puberty (GDPP)
Gonadotropin-independent precocious puberty (GIPP)
Variants of the normal pubertal development
  Isolated precocious thelarche
  Isolated precocious pubarche
  Isolated precocious menarche
o tratamento de escolha da PPDG. A monitorização do tratamento da PPDG é 
realizada pelo exame clínico, avaliação hormonal e exames de imagem. Para o 
tratamento da PPIG, são usadas drogas que bloqueiam a ação dos esteróides 
sexuais nos seus receptores específicos (ciproterona, tamoxifeno) ou bloqueiam 
a sua síntese (cetoconazol, medroxiprogesterona e inibidores da aromatase). 
Variantes do desenvolvimento puberal normal incluem as formas isoladas de 
telarca, pubarca e menarca precoces. Nesta revisão, atualizamos a etiologia,
o diagnóstico e tratamento da precocidade sexual. (Arq Bras Endocrinol 
Metab 2008;52/1:18-31)
Descritores: Puberdade precoce; Análogos de GnRH; Telarca precoce; Pubar-
ca precoce; Testotoxicose; Síndrome de McCune Albright.
INTRODUCTION
PRECOCIOUS PUBERTY IS DEFINED as the development of secondary sexual characteristics before the age of 
8 years in the girls and 9 years in the boys, based on 
European longitudinal studies carried out in the 60’s 
(1). However, the definition of the limits of chronologi-
cal age that define sexual precocity was object of exten-
sive discussion. A study including 17,000 girls suggested 
an adjustment in the mean age of the onset of puberty in 
the United States (2). In this study, based on mothers’ 
reports and photographs, breast and/or pubic hair de-
velopment was present in 27.3% of the African-American 
girls and in 6.7% of the white girls at 7 years of age (2). 
However, a review of 223 patients with sexual precocity 
occurring between 7 and 8 years of age in white girls and 
between 6 and 8 years of age in African-American girls 
found a non-idiopathic form of sexual precocity in 12% 
of the cases, indicating that the finding of sexual charac-
teristics between 6 and 8 years is not necessarily benign 
and warrants investigation and follow-up (3).
When evaluating a child with a clinical picture of 
precocious puberty, the first step consists of the charac-
terization of puberty as gonadotropin secretion-depen-
dent or independent. The differential diagnosis between 
these two types of precocious puberty has direct impli-
cations on the therapeutic option. 
Classification of precocious puberty
Gonadotropin-dependent precocious puberty (GDPP) 
is defined as the premature development of secondary 
sexual characteristics by the premature activation of the 
hypothalamic-pituitary-gonadal axis and gonadotro-
pin-independent precocious puberty (GIPP) occurs 
when premature sexual development is dependent on 
steroid production regardless of gonadotropin secretion 
(Table 1). In addition to these two distinct forms of sex-
ual precocity, three variants of the premature pubertal 
development can occur: isolated precocious thelarche, 
precocious pubarche and precocious menarche.
Isolated precocious thelarche
The term “precocious thelarche” represents the isolat-
ed unilateral or bilateral breast development with no 
other estrogen secretion signs. This is generally a be-
nign clinical condition, occurring from birth to 3 years 
of age, presenting a spontaneous regression within 
months or persisting to puberty. In isolated precocious 
thelarche, bone age and growth velocity remain ade-
quate for chronological age. The physiopathology of 
precocious thelarche is not completely clarified. Base-
line serum gonadotropin and steroid levels are within 
normal prepubertal range, although FSH levels and in-
hibin B can be increased in this condition (4). Pelvic 
ultrasound, a noninvasive tool, may be helpful in distin-
guishing isolated premature thelarche from early-stage 
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precocious puberty in girls (5). The follow-up of girls 
with precocious thelarche is mandatory, since 14% of 
the girls with precocious thelarche may evolve with 
complete sexual precocity (6). Baseline gonadotropin 
and estradiol levels, growth velocity and bone age 
should be periodically evaluated in this condition. The 
treatment of isolated precocious thelarche consists of 
advice to parents and biannual evaluation of patients to 
detect a possible progression into complete puberty.
Isolated precocious pubarche
This condition consists of the appearance of pubic hair 
before 8 years of age in girls and 9 years in boys. The de-
velopment of axillary hair, increased growth velocity and 
slight advancement of bone age can also be observed, 
mainly in the first two years, with a difference of up to two 
years in about 16% of the cases, although progression of 
puberty and final height impairment were not seen. The 
nonclassical form of congenital virilizing adrenal hyperpla-
sia should be ruled out by an ACTH-stimulation test. 
Both prematurity and small for the gestational age status, 
as well as overweight and obesity have been associated 
with precociouspubarche (7,8). In addition, excess weight 
gain in childhood may predispose to precocious pubarche 
in susceptible individuals (9).
Isolated precocious menarche
It is characterized by isolated vaginal bleeding before the 
age of 8 years without other pubertal signs or bone age 
advancement. Such episodes are more frequent during 
the winter and do not present a cyclical character. Go-
nadotropin and estradiol levels are at the normal prepu-
bertal range. A detailed clinical history as well as 
examination of the external genitalia is essential to rule 
out possible genital traumatic injuries or manipulations.
GONADOTROPIN-DEPENDENT
PRECOCIOUS PUBERTY
Gonadotropin-dependent precocious puberty (GDPP) 
mimics the physiological pubertal development, al-
though at an inadequate chronological age. In the 
male, the incresead testicular volume >4 mL (or length 
> 2.5 cm) represents the first clinical manifestation of 
isosexual GDPP. In the female, the increased growth 
velocity and thelarche are the initial events. On the 
other hand, gonadotropin-independent precocious pu-
berty (GIPP) might lead to heterosexual precocious 
puberty (feminization in boys due to high estradiol se-
cretion or virilization in girls due to high androgen 
production). In both isosexual and heterosexual preco-
cious puberty, , the high steroid concentrations deter-
mine the increasing growth velocity and the bone 
maturation, culminating in epiphysis premature fusion. 
This results in excessive stature over childhood fol-
lowed by short stature by adult age in non-treated cas-
es. The estimated GDPP incidence is 1:5.000 - 1:10.000 
(1). The occurrence of precocious puberty is more of-
ten seen in the female (3 to 23-fold), mainly the idio-
pathic gonadotropin-dependent form (1). In the last 
few years, the pivotal role of the kisspeptin-GPR54 sys-
tem in the stimulation of gonadotropin-releasing hor-
mone (GnRH) neurons during puberty was demonstrated. 
An activating heterozygous mutation in GPR54 (R386P) 
was identified in an adopted Brazilian female with GDPP; 
this change is not identified in individuals with normal 
reproductive function having Caucasian, African-Ameri-
can, and Hispanic origin (10,11). Additionally, an activat-
ing mutation (P74S) in the KiSS1 gene encoding GPR54’s 
ligand, kisspeptin, was identified in a Brazilian boy with 
GDPP (10,12). These findings represent the first genetic 
causes of GDPP and should be added to GDPP classifica-
tion (Table 2). Several neurological causes, including hy-
pothalamic hamartomas, central nervous system (CNS) 
tumors, brain development defects, inflammation and 
trauma, can determine sexual precocity. In the male, neu-
rological abnomalities are responsible for 2/3 of the cases 
of precocious puberty, and CNS tumors represent ap-
proximately 50% of the cases. These data indicate the 
need for an efficient neurological investigation in pa-
tients with sexual precocity, particularly in boys (1).
Hypothalamic hamartomas
Hamartomas represent a non-neoplasic congenital mal-
formation, consisting of a heterotopic mass of hypotha-
lamic tissue, located in the base of the brain, in the floor 
of the third ventricle, next to the tuber cinerium or the 
mamillary bodies (13). Immunohistochemistry studies 
revealing the presence of GnRH-positiveneurons in some 
hamartomas led to the hypothesis that these neurons
function as a heterotopic GnRH pulse-generator (14). In 
contrast, in other hamartomas associated with sexual pre-
cocity, no GnRH immunoreactivity was demonstrated, 
but TGFD mRNA and protein, as well as the receptor for 
TGFD, the epidermal growth factor receptor, were de-
tected (14). Approximately 2-28% of the patients with 
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Table 2. Etiology of gonadotropin-dependent precocious puberty.
No CNS abnormalities 
Idiopathic
Genetic causes (GPR54 and KiSS-1 mutations)
Secondary to the previous chronic exposure to sex steroids: (Late treatment of virilizing forms of congenital adrenal 
hyperplasia, after resection of sex steroid-secreting tumors, testotoxicosis, McCune-Albright syndrome)
After exposure to endocrine disrupters
CNS abnormalities
Hypothalamic hamartoma
Tumors: astrocytoma, craniopharingeoma, ependymoma, optical or hypothalamic glyoma, LH-secreting adenoma, 
pinealoma, neurofibroma, dysgerminoma
Congenital malformations: arachnoid cyst, supraselar cyst, hydrocephaly, spina bifida, septum-optical dysplasia, 
myelomeningocele, vascular malformations
Acquired diseases: infections and inflammatory processes of the CNS (encephalitis and meningitis, tuberculosis and 
sarcoidosis granulomas, abscesses, radiation, chemotherapy, head trauma, perinatal asphyxia)
GDPP present hypothalamic hamartomas (1). Clinically, 
hypothalamic hamartomas can be asymptomatic, and 
when symptomatic, the clinical manifestation of sexual 
precocity occurs in approximately 80% of the cases and is 
characterized by the early onset of secondary sexual char-
acteristics (1,13). Neurological manifestations can be as-
sociated with precocious puberty, with gelastic epilepsy 
(typical laughing seizures) being the most common fea-
ture, followed by focal and tonic-clonic seizures. On mag-
netic resonance imaging (MRI), a non-enhanced mass of 
similar intensity to the normal hypothalamus is detected 
(1).The therapy of GDPP due to hypothalamic hamarto-
ma is preferably medical using depot GnRH analogs (13). 
Surgical treatment is reserved for large hamartomas with 
neurological symptoms that are difficult to control or in 
the rare cases of tumor growth (não seria “regrowth”?).
Clinical evaluation
Careful clinical history is important to attain the cor-
rect diagnosis. The age of onset and the rhythm of de-
velopment of secondary sexual characteristics, steroid 
intake, CNS trauma or infections and family history of 
onset of puberty are valuable information. The physical 
examination includes the description of secondary sex-
ual characteristics, along with testis measurement in 
boys and breast development in girls, as well as pubic 
hair development in both sexes, classifying them ac-
cording to Marshall and Tanner criteria (15,16). Tes-
ticular volume > 4 mL or length > 2.5 cm indicates 
testicular stimulation. In GDPP, testicular volume is at 
pubertal size, except in boys below the age of 2 years, 
in whom testicular volume can be still at prepubertal 
size. In contrast, in GIPP, although a reduced testicular 
volume is expected, there are some situations in which 
both testes have an intermediately increased size (testo-
toxicosis, hCG-producing tumors, adrenal testicular 
rests and DAX-1 mutation). Weight and height must 
be evaluated, as well as the statural age, using adequate 
growth curves and calculating height and weight stan-
dard deviation score (SDS) for chronological age by 
appropriate tables. Other physical aspects such as the 
presence of acne, oily skin and hair, axillary hair and 
odor, muscular development and presence of abdomi-
nal and pelvic masses must be evaluated. The presence 
of skin lesions (café-au-lait spots) can be useful in the 
diagnosis of McCune Albright syndrome (gonadotro-
pin- independent precocious puberty due to autono-
mous ovarian cysts, café-au-lait spots and polyostotic 
fibrous dysplasia) or neurofibromatosis (GDPP, skin le-
sions and CNS glyoma).
Hormonal evaluation
The hormonal measurements in basal conditions and 
after stimulation with exogenous GnRH (100 mcg of 
GnRH, i.v) are useful in the diagnosis and differential 
diagnosis of precocious puberty (17). There are several 
available methods for gonadotropin measurements and 
normal values should be established for each method. 
The cut-off values for the immunofluorometric method 
(IFMA) have been established from a population of 
normal individuals (17). Basal LH concentrations >0.6 
U/L for boys and girls are considered enough to estab-
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Table 3. LH cut-off values that indicategonadotropic axis maturation.
Author Protocol
LH peak 
time (min) Method Cut-off value
Oerter KE et al, 1990 (22) LH peak after GnRH (100 µg) NA RIA
>15 U/L (girls)
>25 U/L (boys)
Neely EK et al, 1995 (21)* LH peak after GnRH (100 µg) 30 ICMA
> 5 U/L 
(both genders)
Cavallo A et al, 1995 (23) LH peak after GnRH (100 µg) 30, 45 or 60 IRMA >15 U/L
Eckert et al, 1996 (24) LH peak after GnRH (100 µg) 40 ICMA >8.0 U/L
Brito et al, 1999 (17) LH peak after GnRH (100 µg) 30 – 45 IFMA
>6.9 U/L (girls)
>9.6 U/L (boys)
Brito et al, 2004 (18) LH 2 hs after 3.75 mg of depot leuprolide 120 IFMA >10 U/L (girls)
Resende et al, 2007 (20)* LH peak after GnRH (100 µg) 
30 – 45 ICMA
>3.3 U/L (girls)
>4.1 U/L (boys)
30 - 45 IFMA
>4.2 U/L (girls)
>3.3 U/L (boys)
RIA: radioimmunoassay; ICMA: immunochemiluminometric assay; IFMA: immunofluorometric assay; NA: not available 
*Only normal subjects were included.
lish the diagnosis of GDPP, which dispenses with 
GnRH stimulation test (17). When basal LH levels are 
at prepubertal range (in 37% of the girls with GDPP 
and 29% of the boys in our cohort of 77 children), the 
GnRH stimulation test is indicated. Serum levels of LH 
peak > 9.6 U/L in boys and > 6.9 U/L in girls after 
GnRH stimulation indicate the diagnosis of GDPP 
(17). Alternatively, LH measurement 30 to 120 min-
utes after the first administration of long-acting GnRH 
analog can substitute the classic GnRH-stimulation 
test, however at a higher cost (18). Depot leuprolide 
contains enough free leuprolide to cause a rapid rise in 
serum gonadotropin concentrations (19). We demon-
strated that LH levels >10 U/L (by IFMA) 2 hr after the 
first depot leuprolide acetate injection are also indicative 
of activation of the gonadotropin axis (18). Recently, 
baseline and GnRH-stimulated LH levels measured by 
immunochemiluminometric assays (ICMA) in normal 
subjects demonstrated that this method seems to be 
more sensitive than IFMA, thereby allowing the differ-
entiation between pubertal and prepubertal stage mainly 
in boys under baseline conditions, since the sensitivity of 
LH ICMA assay was 0.1U/L (20). Neely et al. (21) re-
ported that a GnRH-stimulated LH peak measured by 
ICMA greater than 5 U/L was indicative of maturing 
gonadotropin secretion, at least in female subjects, who 
constitute about 90% of children with early puberty. 
However, in that study, 2 SD above the prepubertal 
mean of LH peak for male and female subjects com-
bined was 7.9 U/L (21). Finally, this study suggested 
that a diagnostic cut-off of 8 U/L for GnRH-stimulated 
LH peak in female subjects is a more stringent, and pos-
sibly preferable, threshold for diagnosis of GDPP (21). 
Obviously, the criteria for diagnosis and mainly for 
treatment of GDPP should be a synthesis of several 
clinical factors, as well as the required hormonal confir-
mation. A review of the GnRH-stimulated LH cut-off 
values indicative of maturing gonadotropin secretion 
for the different methods is presented in Table 3. Base-
line and GnRH-stimulated FSH levels are not useful 
for the diagnosis of GDPP, but suppressed levels indi-
cate gonadotropin-independent precocious puberty 
(17). Serum testosterone is an excellent marker of sex-
ual precocity in the male. In contrast, in the female, low 
estradiol concentrations do not rule out the diagnosis 
of precocious puberty, as a significant number of girls 
with sexual precocity (41% in our cohort) had estradiol 
levels within the prepubertal range (17). High estradiol 
levels in the presence of low or suppressed gonadotro-
pin levels strongly suggest the diagnosis of gonadotro-
pin-independent precocious puberty (17). In boys, the 
measurement of the human chorionic gonadotropin 
(hCG) levels must be carried out with the objective of 
diagnosing hCG-producing gonadal and extragonadal 
tumors. Other important measurements include TSH, 
free T4 and adrenal androgen precursors.
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Image studies
Bone age assessment by Greulich & Pyle or Tanner 
methods represents a mandatory tool in diagnosis, fol-
low-up of therapeutic efficacy and final height predic-
tion. In the cases of sexual precocity, regardless of the 
etiology, bone age is advanced in relation to chronologi-
cal age, except in hypothyroidism. In girls, pelvic ultra-
sound allows the assessment of ovarian dimensions and 
the detection of cysts and neoplasic processes. The ana-
tomical evaluation of the CNS in the GDPP cases is car-
ried out preferentially by MRI, since CT is able to 
identify CNS tumors, but not the smaller hamartomas. 
Secondary gonadotropin-dependent 
precocious puberty
It is triggered by the chronic exposure to sex steroids, 
resulting in the acceleration of linear growth, bone age 
and hypothalamic maturation after the primary disease 
treatment. This condition generally occurs when the 
bone age is 10-13 years. The main examples of this 
condition is GDPP that follows sexual steroid suppres-
sion in late-treated patients with virilizing congenital 
adrenal hyperplasia, familial male-limited precocious 
puberty (testotoxicosis) and McCune-Albright syn-
drome.
Previous exposure to endocrine disrupters
Dichlorodiphenyltrichloroethane (DDT)-derived pes-
ticides, which are still used in developing countries, 
may result in premature hypothalamic maturation. In-
creased levels of DDT have been found in adopted girls 
from developing countries with precocious puberty. 
The proposed mechanism is that estrogen activity may 
suppress and mature the hypothalamus; after migration 
to developed countries the exposure to DDT is discon-
tinued, resulting in an increased release of GnRH in 
those girls (25).
Treatment
Precocious puberty treatment has broad objectives, 
which include clinical and psychological aspects, such 
as detecting and treating intracranial expanding tu-
mors, interrupting sexual maturation until the normal 
age for puberty onset, regressing or stabilizing sexual 
characteristics, suppressing the acceleration of skeletal 
maturation, preventing the child’s emotional problems, 
alleviating the parents’ anxiety, delaying the start of 
sexual activity, preventing pregnancy, reducing the risk 
of sexual abuse and decreasing the risk of breast cancer 
associated with precocious menarche. Long-acting 
GnRH agonist analogs are the treatment of choice in 
GDPP (1). They are synthetic analogs of the natural 
GnRH decapeptide. The site of action of such agents is 
the pituitary gland, leading to a reduced number of 
GnRH receptors in the hypophysis. Several GnRH ana-
logs are available, such as leuprolide acetate, goserelin, 
tryptorelin and nafarelin, among others. There is an 
initial stimulation of gonadotropin synthesis and secre-
tion, and when administered chronically, it leads to the 
suppression of gonadotropin production with conse-
quent suppression of the sex steroid production (17). 
Chronic administration of GnRH analogs results in the 
regression or stabilization of secondary sexual charac-
teristics, normalization of growth velocity and reduc-
tion of bone age advancement. The administration 
route and the dose used for the effective blocking of 
the pubertal process depend on the type of analog to be 
used. There are formulations for intramuscular, subcu-
taneous, transdermal implants or nasal administration. 
The adequate dose to reach a satisfactory pubertal 
blocking is still controversial. Our aim is to lower go-
nadotropin values to prepubertal levels, preventing 
complete gonadotropin suppression. The use of leu-
prolide acetate at a dose of 3.75 mg (subcutaneous or 
intramuscular route) every 28 days has been widely 
used, with satisfactory outcomes(26). Only 4% of our 
precocious puberty children treated with GnRH ana-
logs needed an increased dose (7.5 mg/month) to 
control precocious puberty (17,18). Over the last de-
cade, the evidence on the safety and effectiveness of 
GnRH analogs administered quarterly with a 3-fold 
higher dose than the monthly used analogs (11.25 mg 
of leuprolide acetate or 10.8 mg of goserelin) represent 
a more comfortable option for the patient with GDPP 
(27-29). Recently, it was demonstrated that the sub-
dermal GnRH analog (histrelin) implant achieves and 
maintains excellent suppression of peak LH and sex ste-
roid levels for 1 yr in children with GDPP (30,31). The 
side effects of long-acting GnRH analogs include: vag-
inal bleeding after the first doses, nausea and vasomo-
tor symptoms due to hypoestrogenism. Local allergic 
reactions can be found in up to 10% of the patients 
(32). In these situations, the use must be discontinued 
and other treatment options must be instituted, such as 
medroxyprogesterone or cyproterone acetate. It has 
been demonstrated that GnRH analogs do not result in 
weight gain (1,26,33). The treatment monitoring is 
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Table 4. LH cut-off values of different methods for the monitoring of GDPP treatment with depot GnRH analogs.
Author Protocol
LH peak
time (min) Method Cut-off value
Parker KL et al, 1991 (34) LH peak after GnRH (100 µg) 20 – 40 IRMA <1.75 U/L
Cook JS et al, 1992 (35) Nocturnal random LH measurement NA RIA <4.0 U/L
Witchel SF et al, 1996 (36) LH peak after GnRH (100 µg) NA DELFIA <1.75 U/L
Lawson ML et al, 1999 (37) LH after GnRH (100 µg) 40 ICMA <2.0 U/L
Bhatia et al, 2002 (19) LH after depot leuprolide 7.5 mg 40 – 60 ICMA <3.0 U/L
Brito et al, 2004 (18) LH after depot leuprolide 3.75 mg 120 IFMA <6.6 U/L
Brito et al, 2004 (18) LH after GnRH (100 µg) 30 – 45 IFMA <2.3 U/L
Badaru et al, 2006 (38) LH after depot leuprolide 7.5 mg 40 ICMA <4.5 U/L
RIA: radioimmunoassay; ICMA: immunochemiluminometric assay; IFMA: immunofluorometric assay
NA: not available
carried out through clinical examination, hormonal 
evaluation and image assessment. The clinical examina-
tion must aim at verifying the stabilization or regres-
sion of the secondary sexual characteristics, the analysis 
of growth velocity and the examination of the injection 
site. The hormonal evaluation during the treatment of 
precocious puberty with GnRH analogs includes base-
line and GnRH-stimulated measurements (1,18). Base-
line serum LH levels at prepubertal ranges (<0.6 U/L, 
IFMA) and sex steroids, estradiol (<10 pg/mL) in girls 
with previous elevated estradiol levels, and testosterone 
(<14 ng/dL) in boys, indicate adequate suppression of 
puberty (18). Evaluation at baseline conditions is rec-
ommended every 3 months, as well as a stimulation test 
with exogenous GnRH every 6 months (18). After 
GnRH-stimulation test, a value of LH <2.3 U/L sug-
gests a good hormonal control criterion, using the 
IFMA method (18). Some simplified alternatives for 
the treatment monitoring can be used (18). A single 
serum sample for LH drawn 30 to 120 minutes after a 
treatment dose of depot leuprolide is an accurate and 
reliable tool to evaluate treatment efficacy in a manner 
directly comparable with GnRH-stimulation test 
(18,19). We demonstrated, in a group of 18 clinically 
well-blocked GDPP girls, that LH values <6.6 U/L 2 
hours after a 3.75 mg depot leuprolide acetate injection 
suggest good hormonal control (18). Different LH 
cut-off values for GDPP monitoring, as well as differ-
ent protocols, are displayed in Table 4. Bone age must 
be evaluated yearly. The routine US assessment is not 
indicated during GDPP treatment with GnRH analogs, 
except when incomplete pubertal blocking or concom-
itant ovarian processes are suspected. 
Treatment withdrawal
The chronological age for treatment withdrawal has to 
be considered together with the bone age, the psycho-
logical profile and the patient’s and family’s wishes. 
The best results are obtained with GnRH-analog treat-
ment withdrawal between 12 and 12.5 years of bone 
age in girls and between 13 and 13.5 years in boys 
(1,26). A meta-analysis including more than 637 GDPP 
girls treated with GnRH analogs showed that 75% of 
them have reached final height within target height 
range (26). When final height is compared with the 
predicted height at the beginning of the treatment, the 
best results are those obtained in patients who initiated 
treatment earlier (26). However, no positive effects on 
predicted height were obtained after treatment with 
GnRH analogs in girls whose puberty onset was be-
tween 8 and 10 years of chronological age (26). Fewer 
reports are available for males, but they point in the 
same direction (26,39-41). A complete reversibility of 
the hypothalamic-pituitary-gonadal axis suppression af-
ter GnRH-analog therapy withdrawal has been demon-
strated (42). Menarche occurs at variable time periods 
(6-18 months) after treatment withdrawal, being more 
precocious in the girls who had already presented me-
narche before treatment (26). Bone mineral density 
(BMD) is, in most cases, increased for chronological 
age at the moment of the diagnosis and decreases dur-
ing the GnRH agonist treatment or remains unchanged 
(26,42,43). However, at long-term follow-up, BMD 
remains within the normal range for the females when 
they reach final height (26,42,43).
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Table 5. Etiology of Gonadotropin-Independent precocious puberty.
Exogenous use of sex steroids 
Tumors
v hCG-producing tumors: hepatomas, gonadal chorioepithelioma or extragonadal teratomas. 
v Adrenal tumors
v Testicular tumors
v Leydig cell hyperplasia or tumors 
v Ovarian tumors
v Granulosa and theca cell tumors 
Autonomous ovarian cysts
Severe long-term untreated primary hypothyroidism
Genetic causes
Inactivating mutations in CYP21A2 gene
Inactivating mutations in CYP11 and HSD3B2 genes 
Activating mutations in the B-subunit of the Gs protein gene (McCune-Albright syndrome)
Activating mutations in LH-receptor gene (LHR) (testotoxicosis)
Activating and inactivating mutations in the aromatase gene (CYP19)
Inactivating mutations in the glucocorticoid receptor gene (GR)
Congenital Adrenal hypoplasia (DAX-1 mutation)
When the suppression of the pituitary-gonadal axis 
results in marked growth deceleration during treatment 
with GnRH-a (growth velocity below the 25th percentile 
for chronological age), GH (0.15 U/Kg/d) therapy can 
be associated. Two studies showed a real benefit from 
adding GH to GnRH-a therapy in children with de-
creased growth during GnRHa therapy (44,45). Inthese 
two studies, the mean final height was 7.1 and 8.1 cm 
greater than the pretreatment predicted height in the 
first and second report, respectively, and 3.5 and 4.6 cm 
greater than the adult height reached by the control 
group treated with GnRH-a alone, respectively (44,45).
More recently, the association of GnRH-a therapy 
with oxandrolone (0.06 mg/kg·d by mouth), a non-
aromatizable androgen, was described in girls with 
GDPP. In this study, the mean adult height was 7.8 cm 
greater than the pretreatment predicted height and 4.5 
cm greater than the adult height reached by the control 
group (46). However, this excellent result should be 
confirmed in other studies since the group treated with 
GnRH-a alone reached the lowest final height (151.9 ± 
1.2 cm) of all large GDPP cohorts (46).
GnRH receptor antagonists
They immediately block the effect of GnRH and have 
been recently developed for clinical use. They have been 
currently used in assisted reproduction, but experimental 
studies encourage their use in GDPP treatment (47). 
GONADOTROPIN-INDEPENDENT
PRECOCIOUS PUBERTY
Also called precocious pseudopuberty or peripheral 
precocious puberty, gonadotropin-independent preco-
cious puberty (GIPP) is the result of the precocious 
secretion of sex steroids, independently from the acti-
vation of the gonadotropic axis (17). The main causes 
of GIPP are listed in Table 5.
Tumor causes
Testicular Tumors: Leydig cell tumors represent 1-3% 
of all the testicular tumors. They are generally benign; 
however, 10% of them can present malignant behavior. 
The early clinical manifestation of these tumors is pre-
cocious puberty with testicular edema, testis asymme-
try accompanied or not by solid masses. The activating 
mutation of the LH receptor gene (LHR), Asp 578His, 
has been described in several patients with Leydig cell 
tumors (48). High levels of testosterone accompanied 
by prepubertal or suppressed gonadotropin levels con-
firm the diagnosis of GIPP. US is useful to detect tes-
ticular nodules. The surgical approach for tumor 
removal is the treatment of choice. 
Ovarian tumors
Ovarian tumors are rare and are seldom bilateral or 
clinically malignant. Abdominal pain is a frequent clini-
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cal manifestation. Estradiol levels can be remarkably 
elevated, accompanied by suppressed levels of gonado-
tropin. The pelvic US generally allows the diagnosis. 
Mutations in the D-subunit of the Gs protein gene have 
been described in some ovarian tumors (49), as well as 
mutations in the FSH receptor gene (FSHR) (50). 
Ovarian follicular cysts
Follicular cysts secrete estrogens that cause mammary de-
velopment or even acyclic vaginal bleeding. They can be 
recurrent, causing a transitory rise of estradiol levels. Larg-
er follicular cysts can present torsion of the pedicle and 
infarction, requiring surgical intervention. Germline mu-
tations in the FSH receptor gene (FSHR) were not found 
in girls with precocious puberty due to ovarian cysts (51), 
although somatic mutations were not excluded. 
Hypothyroidism
Primary hypothyroidism causing sexual precocity has 
been described for many years in severe and long-term 
untreated primary hypothyroidism associated with 
multiple ovarian cysts. The in vitro demonstration that 
human TSH acts on the wild-type human FSH recep-
tor, and that the response is not dependent upon the 
human FSH receptor isoform, suggests a mechanism to 
explain the precocious puberty in hypothyroidism ac-
companied by extremely increased TSH levels (52,53).
Monogenic causes of sexual precocity
From an etiological point of view, in contrast with GDPP, 
several genetic causes have been identified (54). 
Mutations in the CYP21A2 gene
21-hydroxylase deficiency is responsible for more than 
95% of the cases of congenital adrenal hyperplasia 
(CAH), which is one of the most common autosomal 
recessive disorders. Different CYP21A2 mutations 
cause variable degrees of enzymatic activity impair-
ment, being responsible for the broad spectrum of the 
clinical manifestations of the disease (55). In the male, 
the classical form of 21-hydroxylase deficiency deter-
mines isosexual gonadotropin-independent precocious 
puberty, whereas in the female it causes heterosexual 
GIPP. The nonclassical form of 21-hydroxylase defi-
ciency causes advancement of puberty and bone age in 
the male. In the female, the manifestations include pre-
cocious pubarche, bone age advancement, signs of hy-
perandrogenism, menstrual irregularity, polycystic 
ovaries, acne and hirsutism (55).
Mutations in the CYP11B1 (11-hydroxylase) gene 
and HSD3B2 (E-hydroxysteroid dehydrogenase 2) 
gene
The 11-hydroxylase deficiency is the result of muta-
tions in the CYP11B1 gene and it is clinically character-
ized by virilization with or without hypertension and 
hypokalemic alkalosis. The deficiency of 3-EHSD2 re-
sults from mutations in the HSD3B2 gene and presents 
as incomplete masculinization in the male, whereas the 
genetic female has normal external genitalia or mild cli-
toromegaly. During childhood, hyperandrogenism 
signs can occur in both sexes, represented by preco-
cious pubarche (56).
Mutations in the Gs protein D-subunit gene
McCune-Albright syndrome is a heterogeneous clinical 
condition characterized by a classic triad: gonadotro-
pin-independent isosexual precocious puberty, polyos-
totic fibrous dysplasia and café-au-lait spots. The 
molecular basis of McCune-Albright syndrome consists 
of post-zygotic activating mutations in the Gs protein 
D-subunit gene, leading to mosaicism with a constitu-
tively activated adenylcyclase (57). This missense somat-
ic mutation is almost always characterized by the 
substitution of an arginine residue in position 201 by 
histidine or cysteine. Other hyperfunctional endo-
crinopaties have been described in McCune-Albright 
syndrome, such as GH and/or prolactin-secreting pi-
tuitary adenomas, hyperthyroidism, autonomous adre-
nal hyperplasia and hypophosphatemic osteomalacia. 
McCune-Albright syndrome usually occurs sporadically 
and is more common in girls than in boys (54).
Precocious puberty is independent from gonado-
tropic stimulation, being diagnosed in girls at an early 
age. Suppressed gonadotropin levels associated with 
transitorily high estradiol levels are common hormonal 
findings. Ovarian cysts (asymmetrical and often bilateral) 
are identified at ultrasound, resulting from the follicular 
hyperactivation. The bone disease in McCune-Albright 
syndrome occurs when the bone marrow cells are af-
fected by mutations in the D-subunit of the Gs protein 
gene. X-rays and bone scan are useful tools to evaluate 
bone disease. Markers of bone formation and resorption 
are elevated, mainly if the injuries are multiple. Bisphos-
phonates have been used in the prevention and treat-
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ment of the bone disease in McCune-Albright syndrome. 
Pamidronate treatment in children with severe fibrous 
dysplasia seems to be safe and reduces bone pain, but it 
has no benefits regarding the control of the cystic le-
sions (58).
Familial male-limited precocious puberty
Familial male-limited precocious puberty, also called 
testotoxicosis, is an autosomal-dominant disease caused 
by constitutive activating mutations in the human LH 
receptor gene (LHR) (59,60). The disease generally 
presents at around 2-4 years of age with puberty signs, 
accelerated virilization, excessive growth velocity lead-
ing to short stature by the adult age due to the preco-
cious closure of the epiphyses. Testosterone levels are 
high despite the low levels of basal gonadotropins and 
prepubertal response after exogenous GnRH-stimula-
tion test. This condition treatment consists of drugs 
that block the adrenal and testicular synthesis of andro-
gens (ketoconazol) and/or androgenic receptor block-
age (cyproterone acetate), estrogen receptor blockers 
and aromatase inhibitors.
Mutations in the aromatase gene (CYP19)
The aromatase excess syndrome can cause heterosexual 
precocious puberty and/or gynecomastia in males and 
isosexual precocious puberty and/or macromastia in 
females. The pathophysiology consists of exacerbated 
non-gonadal conversion of androgens into estrogens 
resulting in hyperestrogenism (61). Aromatase defi-
ciency causes pre- and post-natal virilization picture as-
sociated with precocious pubarche, acne and 
advancement of the bone age (62).
Inactivating mutations of the glucocorticoid 
receptor gene
Inactivating mutations of the glucocorticoid receptor 
gene cause a compensatory rise of ACTH with in-
creased adrenal androgens and steroids upon mineralo-
corticoid action. The excessive adrenal androgens can 
rarely lead to the isosexual gonadotropin-independent 
precocious puberty in the male and the heterosexual 
form in the female (54,63). This condition treatment is 
replacement therapy with high dose synthetic gluco-
corticoids, such as dexamethasone, without the intrin-
sic salt-retaining activity (54).
Primary adrenal insufficiency due to DAX-1
(dosage-sensitive sex reversal, adrenal 
hypoplasia congenita (AHC), critical region on 
the X chromosome, gene-1, NR0B1/AHC)
mutation
Primary adrenal insufficiency is a rare condition in pe-
diatric age, and its association with precocious sexual 
development is very uncommon (64,65). Domenice et
al. described a Brazilian boy with X-linked adrenal hyp-
oplasia congenita due to a new frameshift mutation in 
the DAX-1, of which the first clinical manifestation was 
isosexual gonadotropin-independent precocious pu-
berty (66). The extremely elevated ACTH levels were 
supposed to stimulate Leydig cells to secrete testoster-
one, leading to a GIPP in this boy (66). Therefore, 
DAX-1 mutations in humans can promote a dual effect
on pubertal development characterized by GIPP dur-
ing infancy and childhood followed by hypogonadotro-
pic hypogonadism in adulthood (66).
GIPP TREATMENT
Surgical treatment
It is reserved for the previously diagnosed neoplasias, 
such as adrenal, ovarian or testicular tumors, as well as 
hCG-producing tumors of which the surgical removal 
results in regression of the pubertal process. Radiation 
and chemotherapy can be used depending on the type 
of tumor and the clinical indication.
Medical treatment
Drugs that act by blocking the action of sex steroids on 
its specific receptors or through its synthesis are used. 
The therapeutic options include progestational, antian-
drogen and antiestrogen agents: 
Progestational agents
The use of medroxyprogesterone acetate demonstrates 
a beneficial effect in testotoxicosis as well as in McCune 
Albright syndrome in both genders. The mechanism of 
action of medroxyprogesterone includes suppression of 
gonadotropin release and a direct effect on gonadal ste-
roidogenesis by blocking several enzymatic steps. The 
routinely used dose is 10 to 50 mg orally daily or 50 to 
100 mg intramuscularly every two weeks, with the dos-
es being titrated according to the clinical-laboratory 
response. Side effects such as edema, chronic headache, 
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weight gain, purple striae and adrenal insufficiency are 
frequent restricting factors to the clinical application.
Antiandrogen agents
There are two types: androgen receptor blockers and 
androgen synthesis inhibitors. 
Androgen receptor blockers: this category includes 
spironolactone and cyproterone acetate. Both drugs 
have antiandrogenic activity, competing with testoster-
one for its receptor in peripheral tissues and cyproter-
one has an additional progestational action at the 
pituitary level, partially suppressing gonadotropin se-
cretion. The usual daily oral doses are 50 to 100 mg/
m2 for cyproterone acetate and 100 mg for spironolac-
tone. Side effects include: gastrointestinal symptoms 
and gynecomastia in the male. Laboratory hypoadren-
alism can occur with cyproterone use, deserving special 
attention in stressful situations.
Ketoconazol
It is an imidazole derivative that inhibits P450c17 en-
zyme, which converts 17-hydroxyprogesterone into 
androstenedione. The average daily oral dose is usually 
200 mg. Its main side-effect is hepatic injury. Other 
side effects include gastric intolerance, reversibly ele-
vated serum transaminase levels and laboratory hypoa-
drenalism (67). 
Antiestrogen agents
There are two types of agents, the estrogen receptor 
modulators and the estrogen synthesis blockers.
Tamoxifen
It is a selective estrogen receptor modulator and repre-
sents an attractive therapeutic option for the treatment 
of precocious puberty in McCune-Albright syndrome, 
showing a decreased frequency of vaginal bleeding epi-
sodes, reduced growth velocity and decelerated skeletal 
maturation. The dose ranges from 10 to 20 mg/day, 
administered orally (68). Side effects include hepato-
toxicity and hypertricosis. A careful hematological, he-
patic, renal and electrolytic follow-up must be carried 
out quarterly. 
Aromatase inhibitors
The aromatase inhibitors block the conversion of an-
drogens into estrogens. Highly selective aromatase in-
hibitors, such as anastrozole and letrozole, have shown 
to be promising in the treatment of the GIPP in both 
sexes, with few side effects (69,70). Recently, a pilot 
study including nine girls with McCune Albright syn-
drome has suggested letrozole may be an effective ther-
apy for this condition (70). Mean ovarian volume,
estradiol levels, and markers of bone metabolism fell 
significantly after6 months but tended to rise by 24–36 
months (70). In contrast, uterine volumes did not 
change (70). However, in our experience these drugs 
did not prevent estradiol production in 5 girls with 
McCune-Albright syndrome (71). 
The association of an antiandrogen agent (cyproter-
one or spironolactone) with an aromatase inhibitor 
seems attractive despite the high cost. When using drugs 
that inhibit the action of sex steroids such as cyproterone 
and tamoxifen, gonadotropin and sex steroid measure-
ments do not represent good parameters for the thera-
peutic efficacy control. Clinical parameters should be 
always used to monitor GIPP therapy efficacy. 
GnRH agonist analogues
Secondary GDPP is well controlled with the addi-
tion of depot aGnRH. Finally, GIPP treatment in 
both sexes has to be individualized and based on the 
different action mechanisms of the available thera-
peutic options.
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